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AIM OF THE STUDY 
 
 
 
Primary Objective:  
1. To compare the patient, surgical, pathological and treatment characteristics of 
open and laparoscopic surgical staging for adenocarcinoma of the 
endometrium  
2. To analyse the factors affecting the above outcomes after laparoscopic and 
open surgical staging for adenocarcinoma of the endometrium 
 
Secondary Objective:  
To determine the Disease Free Survival (DFS) and Overall Survival (OS) 
after open and laparoscopic surgical staging for adenocarcinoma of the 
endometrium  
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BACKGROUND 
 
The management of gynaecological malignancies forms a major part of any 
surgical oncologist’s practise. Endometrial adenocarcinoma ranks third among 
gynaecological malignancies after cervix and ovarian cancer according to the MMTR 
database. The incidence of endometrial adenocarcinoma is about 2.8/100000 
population. (1) This is in contrast to the US population where it ranks first among the 
gynaecological malignancies is the fourth most common cancer in females after breast, 
lung and colorectal cancers. (2) 
 Two different clinicopathological subtypes of endometrial cancer are recognized: 
the estrogen-related (type I,endometrioid), and the non-estrogen-related (type II, 
nonendometrioid). Endometrioid tumours show microsatellite instability and mutations in 
PTEN, PIK3CA, K-ras, and CTNNBI (β-catenin), while nonendometrioid (predominantly 
serous and clear cell) tumours exhibit p53 mutations and chromosomal instability (3). 
The average age of patients with endometrioid cancer is approximately 63 years, 
and about 70% are confined to the corpus at the time of diagnosis and they have a 5-year 
survival of approximately 83% . In contrast, the average age of patients with 
nonendometrioid cancer is 67 years, and more than 50% have already spread beyond the 
corpus at the time of diagnosis. They have a 5-year survival is approximately 62% for 
clear cell carcinomas and 53% for papillary serous cancers (4). 
 Most patients with endometrial adenocarcinoma present with postmenopausal 
bleeding. The diagnosis should also be considered in patients with postmenopausal 
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presentation of pyometra, peri-menopausal women with heavy inter-menstrual bleed or 
presence of atypical endometrial cells on Pap smear. Endometrial cancer accounts for 
about 15% of all patients who present with postmenopausal bleeding. (5) All patients 
suspected of having endometrial carcinoma should have endocervical curettage and 
endometrial biopsy. A histologically positive endometrial biopsy allows the planning of 
definitive treatment. 
Because there is a false negative rate of approximately 10%, a negative 
endometrial biopsy in a symptomatic patient must be followed by a fractional curettage 
under anesthesia. A diagnosis of endometrial hyperplasia on endometrial biopsy does not 
obviate the need for further investigation. 
Fractional curettage entails bimanual recto-vaginal examination under anesthesia, 
curettage of the endocervical canal, cervical dilatation and systematic endometrial 
curettage. The tissues are placed in a separate container so that the histopathologic status 
of the endocervix and endometrium can be determined separately. 
Routine preoperative investigations for early stage endometrial carcinoma include 
a renal (RFT) and liver function tests(LFT) and a complete hemogram. A pelvic and 
abdominal computed tomographic (CT) scan may be helpful to determine the extent of 
metastatic disease in patients where distant metastases are suspected due to the presence 
of clinical hepatomegaly, altered LFT, palpable abdominal mass or pelvic disease , ascitis 
and high risk histologies. However CT cannot help differentiate the depth of myometrial 
invasion in which MRI scores over CT. 
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The staging of endometrial adenocarcinoma is done according to the 2008 FIGO 
staging which is a surgico-pathological staging system. (6) The 1971 FIGO Staging was a 
clinical one followed by its revision in 1988 which made it a surgico-pathological staging 
and the  subsequent revision has come in 2008 with alteration in stage mainly excluding 
cervical glandular involvement alone and peritoneal cytology as prognostic factors and 
differentiating subgroups of pelvic and para aortic nodal involvement. 
 The foundation of management of endometrial carcinoma is surgery which 
entails a Total abdominal hysterectomy (TAH) with Bilateral salphingo oophrectomy 
(BSO). Extended surgical staging (7) in the form of peritoneal biopsies, omentectomy 
and pelvic and para aortic nodal lymphadenectomy is needed in patients with high-risk 
disease (grade 3, serous or clear cell histologies, stages IC or II disease). This has been 
traditionally achieved by a laparotomy but with the advent of laparoscopy as a surgical 
tool, it has found application in the management of various malignancies and has made 
major strides in the surgical management of endometrial carcinoma also. 
The use of laparoscopy for staging has reduced hospital stay& long term hospital 
costs and facilitated earlier return to normal activity with equivalent oncologic outcomes. 
The pitfalls of operating laparoscopically on obese patients and the issue of nodal yield 
have been found to be improved with increasing experience of the operating surgeon. 
There are few studies on the laparoscopic surgical staging of endometrial 
carcinoma in our country and hence we analysed patients who had been treated by this 
method in our Institute and compared them with patients who underwent open surgical 
staging to evaluate for complications and outcomes in the setting of a tertiary cancer care 
centre.  
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MATERIALS  AND  METHODS 
 
 
A retrospective analysis of all patients who presented with adenocarcinoma of the 
endometrium and treated surgically at the Cancer Institute (WIA) from the year 2006 to 
2010 was done. A total of 145 patients with adenocarcinoma of the endometrium that 
underwent surgical staging by open or laparoscopic method were analysed. Thirty five 
patients with histologies other than adenocarcinoma like squamous cell carcinoma and 
carcino-sarcomas and those with endocervical adenocarcinomas were excluded from the 
study.  
 
  
All patients had a biopsy done by dilatation & curettage to establish a histological 
diagnosis. In some patients the diagnosis was established intra-operatively by frozen 
section study and then surgical staging was done. Pre-treatment evaluation was done by a 
thorough history, physical examination, basic investigations, ultrasound of the abdomen 
and pelvis and a chest X-ray and where necessary a CT scan of abdomen and pelvis. 
 
  
Each patient was evaluated by a multidisciplinary team before therapy was 
initiated. The clinical team included a surgical and radiation oncologist with help from 
our experienced medical oncologists, radiologists and pathologists as and when required. 
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After obtaining an informed consent, treatment was initiated. Patients with high 
grade tumours were treated with one or two fractions of High Dose Rate (HDR) Intra 
Cavitary Application (ICA) brachytherapy. (Heyman et al (8), Sause et al (9), 
Weigenserg et al (10)) 
 
Subsequently they underwent surgical staging two to five days after 
brachytherapy. Surgical staging included peritoneal wash cytology, total abdominal 
hysterectomy, bilateral salphingo oophrectomy, omental and peritoneal biopsies and 
bilateral pelvic lymph node dissection. Pelvic lymph node dissection was done from 
above the level of bifurcation of the common iliac vessels superiorly, to the circumflex 
iliac vein inferiorly, genito-femoral nerve laterally and the bladder medially. This 
dissection encompassed nodes over the common iliac, internal and external iliac vessels, 
and hypogastric and obturator nodes. We did not dissect the para aortic nodes unless they 
were grossly enlarged or unless there was gross pelvic nodal involvement as the 
therapeutic role of para aortic nodal dissection is still a matter of controversy. 
 
 
For the laparoscopic approach five port technique with bilateral para-rectal ports 
and iliac ports and supra-umbilical camera port. The diagnostic laparoscopy is done first 
along with peritoneal fluid cytology followed by the rest of surgical staging as described 
previously. 
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After surgery, all patients with high risk factors for recurrence like grade 3 
tumour, non-endometroid histology, deep myometrial invasion (greater than half of 
myometrium), nodal involvement or cervical involvement by tumour were treated with 
adjuvant radiation. The adjuvant radiation was in the form of external beam pelvic 
radiation to a total dose of 50 Gy with a concomitant vaginal boost of 6 to 8 Gy for some 
patients and addition of para aortic nodal radiation to a dose of 40-41 Gy in patients with 
multiple positive pelvic nodes.  
 
The pelvic radiation was delivered through a CRT (Conformal Radio Therapy) 
Technique by five field method (2 pairs of lateral oblique fields and one anterior field). 
The vaginal boost was delivered by HDR ICA brachytherapy to deliver 600-850 cGy to 
vaginal mucosa. Para aortic nodal radiation was delivered by a field the upper border 
from T12 L1 junction to the lower border concordant with the pelvic field at about the 
level of L5 S1. Patients with multiple positive para aortic or pelvic nodes or peritoneal 
involvement received adjuvant taxane and platin based chemotherapy.  
  
The patients were kept on regular follow up by three-monthly clinical 
examination for the first three years, six monthly visits for the fourth and fifth year and 
annually thereafter. Annual ultrasound of the abdomen and pelvis and chest X-ray were 
also done.  
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The data collected from the case records were analysed using SPSS for Windows 
version 17. 
1. Patient characters like age, co-morbid illnesses and BMI,  
2. Surgical parameters like operating time, blood loss, duration of 
hospital stay and post- operative complications,  
3. Pathological characters like nodal yield, pre operative and post-
operative tumour grade, FIGO stage, uterus and tumour size and  
4. Treatment parameters like use of pre-operative ICA, adjuvant 
radiation, and adjuvant chemotherapy were analysed in the 
laparoscopic and open surgical staging groups. 
 
 Pearson’s Chi-square test by cross table and independent sample T-test were used 
for univariate analysis while Binary Logistic Regression was used for Multivariate 
analysis. Survival analysis was done by the life table method and Kaplan Meir plots. 
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REVIEW OF LITERATURE 
Endometrial adenocarcinoma is the third most common gynaecological 
malignancy after cervix and ovarian carcinomas. In Chennai, the Crude Incidence Rate 
(CIR) of uterine corpus malignancies is 2.8/100,000 according to the MMTR database. It 
has shown a steady increase in Age Standardized Rate (ASR) from 1.6 in 1993 to the 
current ASR of 3.1 with an average annual change of 3.7%. Corpus uterine cancers 
accounted for 3% of all cancers in females. The cumulative lifetime risk of developing 
corpus uterine cancers was 1 in 249(0-74 years). (1) 
 
Epidemiologic Risk Factors for Endometrial Carcinoma (7)  
 
Factors Relative Risk 
Chronic estrogenic stimulation 
   Estrogen replacement  
   (no progestin) 
2-12 
   Obesity 10 
   Early menarche/late menopause 1.6-4.0 
   Nulliparity 2-3 
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Demographic characteristics 
   Increasing age 4 – 8 
   White race 2 
   High socioeconomic status 1.3 
   European/North American country 2 – 3 
   Family history of  
   endometrial cancer 
 
 2 
Associated medical illness 
 
   Diabetes mellitus 3 
   Gallbladder disease 3.7 
   Hypertension 1.5 
   Prior pelvic radiotherapy 8 
 
Patterns of Spread: 
Spread of Endometrial carcinoma occurs by the following routes 
 direct extension to adjacent structures 
 transtubal passage of shed tumour cells  
 lymphatic dissemination  
 hematogenous dissemination  
 Endocervical and trans-cervical extension 
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Prognostic Variables  
Though the stage of disease at presentation is the most important prognostic 
variable in endometrial carcinoma there are other factors that have an impact on disease 
recurrence and survival.  
Some of these are 
1. Age – Greater than 40 years (11) 
2. Histological subtype – non endometroid type (12,13,14,15) 
3. Myometrial invasion – outer half (16) 
4. Vascular invasion – increased recurrence and death in stage I (17) 
5. Peritoneal cytology results – Possibly dependent on other variables (18) 
6. Hormone receptor status – better prognosis even in node positive disease (19) 
7. Nuclear grade – better prognostication than tumour grade (20) 
8. DNA ploidy – Stronger prognostic factor than age and grade (21) 
9. Tumour size – prognostic cut-off at 2 cm (22) 
 
Treatment of Endometrial Cancer 
The management of endometrial cancer has changed significantly over the last 40 
to 50 years. In the 1970s era, endometrial cancer was clinically staged using the 1971 
clinical FIGO staging where Stage IA was uterine corpus confined cancers – uterine 
cavity length <=8cm; Stage IB was uterine corpus confined cancers – uterine cavity 
length >8cm; Stage II was cancers with cervical involvement; Stage III was cancers with 
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extra-uterine spread but still confined to the pelvis and Stage IV was cancers with 
adjacent organ invasion or distant metastases. Patients with early-stage disease were 
treated with preoperative packing of the endometrial cavity with radiation sources, 
Heyman's capsules followed by hysterectomy. (8) 
 
 
The International Federation of Gynecology and Obstetrics (FIGO) approved a 
surgical staging system for endometrial cancer in its revision of staging in 1988. (23) This 
acknowledged the shift to surgery as primary therapy, with pelvic radiotherapy being 
used postoperatively as adjuvant therapy for women at increased risk for recurrence.  
The latest revision of the FIGO staging published in 2009 made the following 
changes 
1. Stage I had only two subgroups - <=1/2 and >1/2 myometrial invasion 
2. Cervical glandular invasion was removed and only stromal invasion was taken 
into consideration and made as Stage II 
3. The involvement of nodes were sub-classified into two groups as Stage 
IIIC1(pelvic nodes) and Stage IIIC2(Para aortic nodes) 
4. Peritoneal cytology was disregarded in the stage grouping  
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Revised FIGO staging for carcinoma of the endometrium. (6) 
Stage I
*
 Tumour confined to the corpus uteri 
  IA
*
   No or less than half myometrial invasion 
  IB
*
   Invasion equal to or more than half of the myometrium 
Stage II
*
 
Tumour invades cervical stroma, but does not extend beyond the 
uterus
**
 
Stage III
*
 Local and/or regional spread of the tumour 
  IIIA
*
   Tumour invades the serosa of the corpus uteri and/or adnexae
#
 
  IIIB
*
   Vaginal and/or parametrial involvement
#
 
  IIIC
*
   Metastases to pelvic and/or para aortic lymph nodes
#
 
    IIIC1
*
 Positive pelvic nodes 
    IIIC2
*
 
Positive para aortic lymph nodes with or without positive pelvic 
lymph nodes 
Stage IV
*
 
Tumour invades bladder and/or bowel mucosa, and/or distant 
metastases 
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  IVA
*
   Tumour invasion of bladder and/or bowel mucosa 
  IVB
*
   
Distant metastases, including intra-abdominal metastases and/or  
inguinal lymph nodes 
*
Either G1, G2, or G3.  
** 
Endocervical glandular involvement only should be considered as 
Stage I and no longer as Stage II. 
# 
Positive cytology has to be reported separately without changing the stage. 
 
The traditional approach for the treatment of endometrial cancer by laparotomy is 
increasingly being replaced by laparoscopic surgery.  Like laparotomy, operative 
laparoscopy can accomplish the full surgical procedure, which includes doing a complete 
intra-peritoneal survey, obtaining peritoneal washings, removing of the adnexae and 
performing pelvic and para aortic lymphadenectomy and total hysterectomy. The 
advantages of laparoscopy are well-documented. Laparoscopy avoids the morbidity of a 
laparotomy, overcomes the limitations of vaginal hysterectomy, provides adequate histo-
pathological information for accurate surgical staging and hastens the postoperative 
recovery of patients.  
 
The performance of a pelvic and para aortic lymphadenectomy is the key 
procedure for the staging of this cancer. In 1989, Dargent and Salvat (24) from France 
used the laparoscope to perform limited pelvic lymphadenectomy in women with cervical 
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cancer. In 1991, Childers and Surwit (25) published their report on pelvic and para aortic 
lymphadenectomy performed along with a laparoscopic assisted vaginal hysterectomy 
(LAVH) and bilateral salphingo-oophorectomy (BSO) in two women with endometrial 
cancer.   
Childers et al. (26) reported their series of 59 patients with endometrial cancer 
who were staged laparoscopically combined with a vaginal hysterectomy and bilateral 
salphingo-oophorectomy. Among them thirty- one patients were deemed candidates for 
staging based on criteria like high-grade or deep myometrial invasion and  lymph node 
dissection was completed in 29 patients (obesity precluded it in two patients), with a 
feasibility rate of 93%. There were three major and three minor complications. The 
average hospital stay was 2.9 days, but there was no data on operative time, lymph nodal 
yield, and cost analysis. These early series emphasized pelvic lymphadenectomy, but it 
remained necessary to do laparoscopic para aortic lymphadenectomy for laparoscopy to 
be fully accepted as a technique to stage endometrial cancers.  
Childers et al. (27) published their experience in para aortic lymphadenectomy 
extending from the duodenum to the bifurcation in 61 patients with cervical, endometrial, 
or ovarian cancer in 1993. Obesity prevented the completion of the surgery in three 
patients (5%) and in one patient (0.8%), conversion was needed in view of extensive 
adhesions.  
Data on lymph node yield were available in 23 patients. For the right-sided 
dissection, there was an average nodal yield of three. The operating time for 
lymphadenectomy for the six patients who underwent para aortic lymphadenectomy 
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ranged from 25 to 70 minutes, depending on the unilateral or bilateral nature of 
procedure. The hospital stay for the 33 patients undergoing laparoscopic 
lymphadenectomy was 1.3 days. There was one vena caval injury that required 
transfusion and laparotomy, a complication rate comparable with that of open surgery. 
Two patients had complications related to the hysterectomy: One had a transected ureter 
caused by the endoscopic stapler, and one had a cystotomy. 
In 1995, Spirtos et al. (28) reported on 40 patients who underwent bilateral partial 
para aortic nodal sampling. There were five conversions to laparotomy in their study - 
two to remove unsuspected metastases, two for control of hemorrhage, and one because 
of equipment failure. The left-sided dissection was judged to be inadequate in two 
patients, which was an overall failure rate of 12.5%. On an average eight para aortic 
lymph nodes was removed: four from the right side and four from the left side. The mean 
operative time was 3 hours, 13 minutes, and the average hospital stay was 2.9 days.   
In one of the largest series of laparoscopic lymphadenectomy, Koehler et al.(29) 
published their report on 650 patients undergoing laparoscopic transperitoneal pelvic (n = 
499) or para aortic (n = 468) (combined pelvic and para aortic n = 362) 
lymphadenectomies. The mean number of pelvic lymph nodes removed from 1994 to 
2003 remained fairly constant (16.9-21.9). On the contrary, the mean number of para 
aortic lymph nodes increased from 5.5 in 1994 to 18.5 in 2003, reflecting improvements 
in technique with increasing experience. The incidence of intra-operative complications 
(bowel or vessel injury) was 2.9% of patients while the incidence of postoperative 
complications was 5.8% with an overall complication rate of 8.7%. The authors reported 
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that no major intra-operative complications were encountered during the last five years of 
the study. 
Similar results were reported by Querleu et al. (30) in their experience with 
transperitoneal and extraperitoneal lymph node dissections in 1,000 gynecologic cancer 
patients. There were 777 pelvic (757 transperitoneal, 20 extraperitoneal) and 415 aortic 
lymphadenectomies (155 transperitoneal, 260 extraperitoneal) in this study on patients 
with cervical, vaginal, endometrial and ovarian carcinoma. There were 182 patients with 
endometrial carcinoma. The average number of pelvic lymph nodes removed was 18 via 
a transperitoneal approach and the average number of para aortic lymph nodes removed 
was 17 via a transperitoneal approach versus 21 via an extraperitoneal approach. The 
authors reported an increase in the number of lymph nodes removed with increasing 
experience, yielding an average of 24 pelvic and 22 aortic lymph nodes in 2003. Intra-
operative complications occurred in a total of 2% of patients including injury to vascular 
structures (1.1%); bowel (0.3%); ureter (0.3%); and nerves (0.3%). Five patients 
underwent conversion to laparotomy for completion of the lymph node dissection, 
secondary to fixed nodes or extensive adhesions. Conversion to laparotomy occurred in 
an additional two patients secondary to bowel or ureteric injury. Five patients required a 
second surgical intervention due to postoperative complications, most commonly bowel 
obstruction (n = 4). 
These studies have demonstrated the ability of laparoscopic surgeons to perform 
pelvic and para aortic lymphadenectomy. The American Medical Association Physicians 
Current Procedure Terminology (CPT 2007) lists a total of four laparoscopic lymph node 
  
22 
 
dissection procedures, including total pelvic lymphadenectomy and para aortic lymph 
node sampling. Laparoscopic surgery has been used by many oncologic surgeons, and 
has been applied to nearly every disease site in gynecologic oncology. 
Spirtos et al. (31) reported on 13 patients who underwent laparoscopic staging and 
hysterectomy as compared to 17 patients who underwent laparotomy. The laparotomy 
group required significantly longer hospitalization, (6.3 vs. 2.4 days, p <0.001), took 
longer to return to normal activity (5.3 weeks vs. 2.4 weeks, p <0.0001) and incurred 
higher overall hospital costs ($19,158 vs. $13,988, p <0.05). The patients having 
laparotomy were significantly more obese and had a higher body mass index (BMI) (30.2 
vs. 24.2).  
The advantages with laparoscopic staging include significantly shorter post- 
operative stay, faster recovery and earlier return to activity coupled with lower overall 
cost. The longer operating time needed for laparoscopic staging is related to the 
experience of the surgeon as has been shown by Mendelez et al (32). In their study on 
laparoscopic staging for endometrial cancer, the operative time for staging decreased 
from a mean of 196 minutes for the first 25 patients to 128 minutes for the last 25 
patients. Hospital stay decreased from 3.2 days to 1.8 days. The decrease in operative 
time with increasing experience and decreased hospital stay, coupled with the diminished 
use of expensive, disposable instruments, has led to a significant cost savings for 
laparoscopy.  
One commonly quoted limitation of laparoscopic surgery is its use in patients 
with higher BMI as is the case with most patients with adenocarcinoma of the 
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endometrium who often have BMI greater than 35. As surgical skills have grown, 
laparoscopy has been used successfully in these women. Holub et al. (33) completed 
staging laparotomy for endometrial cancer successfully in 94.4% of 33 patients with 
BMIs of 30 to 40. Eltabbakh et al. (34) completed laparoscopic surgical staging in 88% of 
42 women with BMIs of 28 to 60. In both studies, the benefits of shorter hospital stay 
with faster recovery were verified. However, many retrospective studies comparing 
laparoscopy and laparotomy have reported a significantly lower BMI in patients 
undergoing laparoscopic management, reflecting a selection bias favoring open 
procedures in obese patients. 
Long-term survival and recurrence have been reported in several papers by 
Eltabbakh et al,(35) Malur S et al(36), Obermair et al (37) Zapico et al (38) and 
Kalogiannidis et al (39). In these series, more than 900 patients have been studied for a 
median of 16 to 53 months. The recurrence rate following laparoscopic management 
ranged from 0% to 9%. When compared to historical controls undergoing laparotomy and 
adjusting for factors such as stage, grade, age, and weight, there was no difference in 
survival in any of these studies.  
In the study by Eltabbakh et al, (35) one hundred women had laparoscopic 
surgical staging and 86 underwent open surgical staging. There were no significant 
differences in the two groups in terms of patient factors like age, menopausal status, 
parity or tumour factors like histology, surgical stage, tumour grade or surgical factors 
like lymphadenectomy and use of postoperative radiation therapy. Women who 
underwent laparoscopic staging and those who had open surgical staging had 2-year and 
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5-year recurrence-free survival rates of 93% vs. 94% and 90% vs. 92%, respectively. 
There was a similar trend in 2-year overall survival (98% vs. 96%) and 5-year overall 
survival rates (92% vs. 92%, respectively). Between both groups, there was no difference 
with regard to the site of recurrence.  By univariate and multivariate analyses, the 
approach used did not have any impact on survival. Only tumour grade, surgical stage, 
and histology were found to have a significant effect on survival. 
In Germany, Malur et al. (36) prospectively compared thirty-three patients who 
were treated by conventional laparotomy to thirty-seven patients treated by a laparoscopic 
assisted vaginal approach. There was no significant difference between the two groups 
with regard to the number of lymph nodes, mean body mass index and mean operating 
time. The mean follow-up for the laparotomy group was 21.6 months compared to 16.5 
months for the laparoscopy group. The recurrence-free survival rate was 97.3% for the 
laparoscopy group and 93.3% for laparotomy group and it was not statistically 
significant. Similarly, the overall survival rate was 90.9% in the laparotomy group and 
83.9% in the laparoscopic group  
Tozzi et al. (40) published the first report on survival out-comes in endometrial 
cancer from a randomized, prospective clinical trial analyzing laparotomy versus 
laparoscopy. With a median follow-up of 44 months, the authors reported that patients 
with stage I endometrial cancer had disease-free survival rates 93.8% (in the laparotomy 
group) and 91.2% (in the laparoscopic group). The overall survival rate was not 
statistically significant at 89.7% versus 86.3%, respectively. 
  
25 
 
The landmark prospective Randomized Control Trial comparing the laparoscopic 
and open surgical staging was the multi institutional GOG - LAP 2 trial by Walker et al. 
(41) The conversion rate was 25.8% (394 patients)( Due to bleeding in 49 patients (2.9%) 
poor visualisation in 246 patients (14.6%), metastatic disease in 69 patients (4.1%) and 
miscellaneous causes in 70 patients (4.2%)). Laparoscopy had fewer postoperative 
complications than laparotomy (14% v 21%, respectively; P < 0.0001) but similar rates of 
intra-operative complications. The median operative time was significantly in the 
laparoscopy group (204 v 130 minutes, P < 0.001). In the laparoscopy group the duration 
of hospital stay was significantly shorter (52% v 94%, respectively; P <0.0001). This 
study indicates that surgical staging for endometrial adenocarcinoma can be performed 
with laparoscopy with fewer postoperative complications, shorter hospital stay and 
without increased risk of intra-operative injuries. 
The update to the study dealing with recurrence and survival was published online 
in January 2012. (42) There were 309 recurrences (210 in laparoscopy group; 99 in the 
laparotomy group) and 350 deaths (229 in the laparoscopy group; 121 in the laparotomy 
group) with a median follow-up of 59 months in 2,181 patients still alive. The hazard 
ratio for laparoscopy relative to laparotomy was 1.14 (90% lower limit, 0.92; 95% upper 
limit, 1.46), thus not meeting the definition of non-inferiority (falling short by 0.14) as 
specified in the protocol. However, the actual recurrence rates were substantially lower 
than anticipated, resulting in an estimated 3-year recurrence rate of 10.2% with open 
surgery group and 11.4% with laparoscopy group or a difference of 1.14% (90% lower 
limit, -1.28; 95% upper limit, 4.0). The 5-year overall survival was almost the same in 
both arms at 89.8%.  
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There are two meta-analyses that have compared the two techniques of surgical 
staging. In the analysis by Palomba et al. (43) four Randomised Control Trials (RCT) 
were identified and included for analysis. There was no significant difference in the 
laparoscopic and open approaches to endometrial cancer in disease-free survival (OR = 
0.76, 95%CI 0.34 to 1.72, P = 0.655) overall survival [odds ratio (OR) = 0.80, 95%CI 
0.37 to 1.70, P = 0.695] or cancer-related (OR = 0.89, 95%CI 0.19 to 4.13, P = 0.815) 
survival. The operative time was significantly longer (OR = 53.48, 95%CI 37.28 to 
69.68, P = 0.0002), the intra-operative blood loss significantly lower (OR = - 266.86, 
95%CI - 454.82 to - 78.90, P = 0.005) as were the post-operative complications (OR = 
0.40, 95%CI 0.23 to 0.70, P = 0.007) associated to laparoscopy. There was no effect due 
to laparoscopy on pelvic (OR = 0.62, 95%CI - 1.47 to 2.71, P = 0.560) and para aortic 
(OR = 1.49, 95%CI - 2.49 to 5.60, P = 0.477) lymph nodal yield, and intra-operative 
complications (OR = 1.60, 95%CI 0.49 to 5.22, P = 0.390). 
In the other meta-analysis by H Zhang et al (44) eight Randomised trials were 
included, with 3599 patients in total. No significant difference was observed between 
laparoscopy and laparotomy in overall (odds ratio [OR], 0.96; 95% confidence interval 
[CI], 0.50–1.82; P = 0.892), disease-free (OR, 0.96; 95% CI, 0.50–1.82; P = 0.892), or 
cancer-related (OR, 0.90; 95% CI, 0.27–3.08; P = 0.871) survival. More intra-operative 
complications (OR, 1.33; 95% CI, 1.03–1.73; P = 0.030), fewer post-operative 
complications (OR, 0.59; 95% CI, 0.46–0.75; P < 0.001), longer operative time 
(standardized mean difference [SMD], 0.80; 95% CI, 0.46–1.15; P < 0.001), lower blood 
loss (SMD, –2.29; 95% CI, –3.67 to − 0.91; P = 0.001), and shorter hospital stay (SMD, 
–2.60; 95% CI, –3.47 to − 1.72; P < 0.001) were associated with laparoscopy. There was 
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no significant difference between the groups in pelvic (SMD, 0.22; 95% CI, –0.03 to 
0.48; P = 0.086) or para aortic (SMD, 0.54; 95% CI, –0.04 to 1.11; P = 0.067) lymph 
node yield. 
The conclusion from these studies and meta-analyses is that laparoscopic 
approach should be considered as safe and effective a procedure as the open surgical 
approach for patients with early stage endometrial cancer. In spite of longer operative 
times, the advantages of laparoscopy over traditional laparotomy are seen in reduced 
intra-operative blood loss and postoperative complications. Similar to the surgical 
management of colorectal cancers where laparoscopic surgery has been proved to have 
many short term advantages with equivalent long term oncologic outcomes it will emerge 
to be a likely alternative to laparotomy for early endometrial cancer. 
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RESULTS 
Patient Characteristics 
Age Distribution 
 The median overall age of the patients in our study was 55 years with the 
laparoscopy group having a median age of 59.5 years and the open group having the 
median age as 55 years. There was no significant difference in the two groups by 
independent Samples T-test. (p=0.35) 
Median Age  Years 
Laparoscopy Group 59.5 
Open surgery Group 55 
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Body Mass Index (BMI) 
The overall median BMI was 27.82 while in the laparoscopy group it was 29.09 
and the open surgical staging group it was 26.91. There was no significant difference in 
the two groups by independent Samples T-test. (p=0.07) 
 
Group Median BMI 
Laparoscopy Group 29.09 
Open surgery Group 26.91 
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Co-Morbid conditions 
 There was no significant difference in the occurrence of co-morbid illnesses in the 
two groups (p=0.39)  
Co-morbid condition Open Surgery group Laparoscopic surgery group 
Diabetes Mellitus 15 3 
Hypertension 16 4 
Ischemic Heart Disease 3 0 
Multiple co-morbidities 35 15 
Others 4 3 
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Surgical parameters 
Type of surgery 
 Of the 145 patients operated during the time period from 2006 to 2010, 103 
patients underwent open surgical staging while 42 patients were staged laparoscopically. 
Group Number of patients 
Laparoscopy Group 42 
Open surgery Group 103 
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Operating time 
 The median operating time was significantly different in the two groups- it was 4 
hours in the laparoscopic surgery group and 2.5 hours in the open surgery group 
(p<0.001). 
 
Blood loss 
 The median blood loss in both the laparoscopic and open surgery patient groups 
was 300 ml (p=0.577) 
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Hospital Stay 
 The median duration of hospital stay was 7 days (range 5-42 days) in the 
laparoscopic surgery group while it was 12 days(range 9-29 days) in the open staging 
group and it was found to be statistically significant (p<0.001) 
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COMPLICATIONS 
 There were 35 complications overall, with 30 occurring in the open surgery group 
and 5 in the laparoscopic surgery group. 
Complication Open Surgery Laparoscopic surgery 
Wound complications 19 0 
Organ Injury 0 1(ureteric injury) 
Pelvic collection 2 1 
Repeat Surgery 1 (Wound dehiscence repair) 1(ureteric reimplantation) 
Ileus 3 0 
Others 5 3 
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There was significant difference (p=0.028) in the incidence of complications 
between the two groups of patients. The most common complication in the open surgery 
group was wound infection and re-suturing (19 patients). Pelvic collection occurred in 
two patients in the open surgery group and in one patient in the laparoscopic staging 
group. All of these were managed conservatively.  
 
There was one ureteric injury necessitating a ureteric re-implantation in the 
laparoscopy group. Interestingly all the complications in the laparoscopy group occurred 
in the first ten patients after which there were no complications. There were two 
conversions in the laparoscopy group both in view of intra operative bleed. Other 
complications included urinary tract infection (5 patients), post operative cardiac 
ischemia (1 patient), atrial flutter (1 patient) and respiratory infection (1 patient). Post 
operative paralytic ileus delaying oral feeds occurred in three patients who underwent 
open surgical staging. 
The following factors were considered to be confounding factors that may 
independently increase the occurrence of complications following surgery. 
1. Use of pre operative ICA 
2. Presence of co-morbid conditions  
3. High BMI 
4. Long duration of surgery 
5. Increased Blood loss  
6. Total number of pelvic nodes removed 
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Univariate and multivariate analysis did not reveal any significant difference in 
these factors between the two groups essentially proving that the observed  difference in 
the incidence of complications were due to the type of surgical technique used and not 
due to any other factor.   
On subgroup analysis, among patients who underwent open surgical staging, 
number of pelvic nodes removed was found to be a significant factor in relation to 
occurrence of complications (p=0.015) and in those with laparoscopic staging use of pre-
operative ICA was found to be significant (p=0.035) on univariate analysis. It was also 
found that the hospital stay was prolonged in those patients with complications to a 
significant degree (p=0.003 in open surgical staging and p<0.001 in laparoscopic staging) 
Pathological Parameters 
Pre operative Grade 
 The preoperative grade determined from the biopsy of the lesion showed that 
grade 2 was the most common grade among both the groups. There was no statistical 
significant difference in the distribution of grades in the two groups. (p=0.461) 
 In three patients in the open surgical group and one patient in the laparoscopic 
group, the tumour was identified intra-operatively after a frozen section study of the 
tumour from the hysterectomy specimen subsequent to which the rest of the staging was 
completed in the same sitting. 
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Pre Operative Grade Open surgery group Laparoscopy group 
Grade 0 (Intra op identification of 
tumour) 
3 1 
Grade 1 16 5 
Grade 2 68 33 
Grade 3 16 3 
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Post operative grade 
 There was a change in the post operative grade compared to the pre operative 
grade in 39 patients. In 15 patients it was downgraded of which 4 patients did not have 
any tumour in the final resected specimen. For 24 patients there was an escalation of the 
tumour to a higher grade in the postoperative histopathology highlighting the discordance 
between pre operative and final grade of the tumour.  
Post Operative Grade Open surgery group Laparoscopy group 
Grade 0 (Intra op identification of 
tumour) 
1 3 
Grade 1 10 1 
Grade 2 75 33 
Grade 3 17 5 
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Specimen and tumour size 
 There was no significant difference in the median size of the uterus specimen (9 
cm in the open group vs. 8.5 cm in the laparoscopy group) (p=0.075) or tumour size 
(Median size 3.5 cm in both groups) (p=0.091) ascertaining that the presence of a bulky 
uterus is not a deterrent to the performance of laparoscopic staging. 
Stage Distribution 
Most patients in both groups had Stage 1 endometrial cancer constituting 76% and 
69% of the open and laparoscopic groups respectively.  
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 Stage Open Surgery  Laparoscopic staging 
1 78 (76%) 29(69%) 
2 11(10.5%) 11(26%) 
3 12(11.5%) 1(2.5%) 
4 2(2%) 1(2.5%) 
  
  
Nodal yield 
 The median number of pelvic nodes removed in the entire study group was 13 
nodes. The median number of pelvic nodes removed in the open surgery group was 12 
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nodes (range 3 to 30 nodes) and the figure for the laparoscopic surgery group was 13 
nodes (range 4 to 41 nodes) (p=0.488 by Independent samples t- test). In the laparoscopic 
staging group the median number of pelvic nodes removed improved from 10 in the 
initial 21 cases to 16 in the next 21 cases reflecting the increasing nodal yield with 
crossing of the learning curve.  
 Open Surgery group Laparoscopic surgery group 
Median 12 13 
Minimum 3 4 
Maximum 30 41 
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Treatment Parameters 
Pre operative Radiation 
 Patients with high grade histology were treated with one or two sittings of HDR 
brachytherapy by Intra Cavitary application (ICA). Sixty eight patients in the open 
surgery group and fourteen patients in the laparoscopic staging group received pre 
operative ICA.  
 
Adjuvant Radiation 
 Patients with high risk features like deep myometrial invasion, pelvic nodal 
involvement, cervical involvement or non endometroid histology received adjuvant 
radiation.  
Open Surgery group Laparoscopy Group
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59 patients received external beam pelvic radiation alone while 11 received 
additional vaginal boost. 3 patients had pelvic and para aortic nodal radiation while a 
similar number had radiation to all three regions. One patient received vaginal 
brachytherapy only while one patient was detected to have metastases in the pubic ramus 
and treated by external beam radiation.  
 
Type of Adjuvant RT Overall Open Surgery 
group 
Laparoscopic 
group 
Pelvic 59 44 15 
Pelvic +Vaginal boost 11 7 4 
Pelvic + Para aortic 3 3 0 
Pelvic +vaginal+ Para 
aortic 
3 2 1 
Others 2 0 2 
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Adjuvant Chemotherapy 
Doublet chemotherapy with Taxol and carboplatin was used in six patients with 
gross pelvic nodal positive disease, para aortic nodal disease and omental disease and one 
patient with a synchronous ovarian malignancy while carboplatin alone was used in one 
patient with gross pelvic nodal disease.   
Tamoxifen induced endometrial cancer 
 Tamoxifen induced endometrial cancer constituted 8.3% of the entire study 
population. There were twelve patients who had previously been treated for carcinoma 
breast and presented with tamoxifen induced endometrial carcinoma. The median 
duration of tamoxifen use was 5 years. (Range 2 to 10 years). The median time to 
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develop to uterine malignancy after treatment of carcinoma of the breast was 5 years 
(range 2 to 14 years). 
SURVIVAL ANALYSIS 
Overall Survival (OS) 
The overall survival was calculated from the date of completion of treatment to 
the date of last follow up in all patients who are still alive or are lost to follow up and 
from the date of completion of treatment to the date of death in all patients in the study 
whom death occurred due to any cause.  
 
 
The median Overall Survival (OS) in the laparoscopy group was 2.26 years and 
4.14 years in the open surgical group. This was not statistically significant when the 
Median OS Median DFS Median Follow up
4.14 4.12
3.27
2.26 2.15
1.67
SURVIVAL & FOLLOW UP
Open Surgery Laparoscopic Surgery
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analysis was done by life table method. (p=0.735). The shorter overall survival in the 
laparoscopy surgery is due to the fact that laparoscopic surgery was done only from 2008 
and the median follow up was only 1.67 years whereas it was 3.27 years for the open 
surgery group  
Type 1 = Open Surgery Type 2 = Laparoscopic Surgery 
Life Table for Overall Survival – P=.735 
First-
order 
Controls 
Interval  
Start  
Time 
Number 
Entering 
Interval 
Number 
Withdrawing 
during Interval 
Number 
Exposed 
 to Risk 
Number 
 of  
Terminal 
Events 
Proportion 
Terminating 
Proportion 
Surviving 
Cumulative 
Proportion 
Surviving at  
End of 
Interval 
Type of 
surgery 
1 
0 103 1 102.500 5 .05 .95 .95 
1 97 9 92.500 1 .01 .99 .94 
2 87 6 84.000 0 .00 1.00 .94 
3 81 16 73.000 2 .03 .97 .92 
4 63 37 44.500 0 .00 1.00 .92 
5 26 26 13.000 0 .00 1.00 .92 
2 
0 42 0 42.000 1 .02 .98 .98 
1 41 16 33.000 0 .00 1.00 .98 
2 25 18 16.000 0 .00 1.00 .98 
3 7 6 4.000 1 .25 .75 .73 
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Disease Free Survival 
 The DFS was calculated from the date of completion of treatment to the date of 
recurrence in patients with recurrences and from date of completion of treatment till the 
date of last follow up in all other patients.  The median DFS for the laparoscopic surgery 
group and the open surgery group were 2.15 and 4.12 years respectively. Life table 
method did not show any statistical significance. (p=0.589)  
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Type 1 = Open Surgery Type 2 = Laparoscopic Surgery 
Life Table for Disease Free Survival – P=0.589 
First-
order 
Controls 
Interval 
Start 
Time 
Number  
Entering  
Interval 
Number  
Withdrawing  
during  
Interval 
Number  
Exposed  
to Risk 
Number  
of 
Terminal 
Events 
Proportion 
Terminating 
Proportion 
Surviving 
Cumulative 
Proportion 
Surviving 
at End of 
Interval 
Type of 
surgery 
1 0 34 1 33.500 1 .03 .97 .97 
1 32 9 27.500 1 .04 .96 .93 
2 22 6 19.000 1 .05 .95 .89 
3 15 15 7.500 0 .00 1.00 .89 
2 0 42 1 41.500 1 .02 .98 .98 
1 40 16 32.000 0 .00 1.00 .98 
2 24 17 15.500 2 .13 .87 .85 
3 5 5 2.500 0 .00 1.00 .85 
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 Recurrences  
 Other than the three patients who died of advanced disease there were seven 
recurrences – a total of eight in the open surgery group and two in the laparoscopy group. 
There were three regional recurrences that occurred in the pelvic nodes which were 
salvaged by radiation in the laparotomy group. There was no significant difference in the 
recurrence rate (p=0.517) in the two groups.  
Site Open Surgery Laparoscopic Surgery 
Lung 3  
Liver 1 1 
Brain 1 1 
Regional recurrence 3  
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MORTALITY 
There were ten deaths in the study population eight in the open surgery group and 
two in the laparoscopic surgery group. Of the ten deaths, two were not related to 
malignancy and four were due to metastatic carcinoma breast in patients who developed 
carcinoma endometrium after previous treatment for carcinoma breast.  
In one patient the cause of death was not known. In the three attributable to 
advanced carcinoma endometrium, death was as a result of lung, brain and liver 
metastases respectively. 
 
 
 
 
 Open Surgery Laparoscopic Surgery 
Lung 1  
Liver  1 
Brain 1  
Non Cancer Cause 2 1 
Advanced carcinoma 
Breast 
4  
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DISCUSSION 
  
 The median age of our study population was 55 years (Range 30-79 years) and 
not statistically different between the laparoscopy (median 59.9 years, range 32-79years) 
and open surgery (median 55 years, range 30-77 years) groups. In the studies in Western 
population by Eltabbakh et al (35), Ghezzi et al. (45) Volpi et al (46) the median age was 
about 63 years whereas in the studies on Asian population like Lee et al (47) and Tay (48) 
the median age was similar to our study being about 51 years. 
 
 
 In the Western studies mentioned above, the study population tended to have 
higher BMI of more than 30 while in our study it was 28 which was closer to the value of 
around 26 in the data on Asian patients by Lee et al (47) and Tay (48). This probably 
reflects the geographic difference in the study population. In contrast to most of the above 
mentioned studies where the median BMI tended to be lower in the laparoscopy group,  
in our study the median BMI was higher in the laparoscopy group (median 29, range 19-
39) than in the open surgery group (median 27, range 16-53) though it did not reach 
statistical significance (p =0.07) 
 
 Our median operating time for laparoscopic staging was 4 hours (range 3-7 hours) 
and 2.5 hours for the open surgery group (range 2-5 hours). In comparison to the studies 
by Lee et al (47) and Eltabbakh et al (35) it was longer by about 60 minutes probably 
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reflecting our learning curve as laparoscopic surgical staging was started in our institute 
only in 2008. 
 
 The estimated median blood loss in our study was 300 ml in both the groups 
(range 100 to 1200ml for open surgery group and 50-800 ml for the laparoscopy group). 
Post operative blood transfusion was required in 2 patients in the laparoscopy group 
(4.7%). This was more than the blood loss of 150 ml mentioned by Eisenhauer et al (49) 
but comparable to the blood loss of about 280-300ml mentioned by Lee et al (50), 
Eltabbakh et al (35). Our blood loss has been comparatively higher in the laparoscopy 
group again reflecting our learning curve for the procedure. 
 
 The median hospital stay was significantly less in the laparoscopic staging group 
at 7 days (range 5-42 days) compared to the open surgical group at 12 days (range 9-29 
days). These results were consistent with the various studies quoted above showing a 
shorter post operative stay for laparoscopic staging thus demonstrating that laparoscopic 
technique is associated with earlier discharge from the hospital. Studies also showed that 
laparoscopy is associated with earlier return to normal activity compared to laparotomy 
as well as reduced total overall costs. (Spirtos et al. 51) (Gemignani et al. 52) 
  
 In the LACE study, (53) in the early recovery phase (upto four weeks post 
surgery), patients with laparoscopic hysterectomy experienced a clinically and 
statistically significantly greater improvement in most Quality of life measurements, 
compared to patients receiving open surgery.  During the late post-operative recovery 
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phase (3 to 6 months post surgery), patients with laparoscopic surgery compared to 
patients with open surgery recovered significantly more in their physical (p=0.008), 
functional (p=0.009), endometrial cancer-specific (p=0.003), and overall well-being 
(FACT-G) (p = 0.03), and also experienced superior Quality of life recovery with regards 
to body image (p=0.001). 
 
 There was significant difference (p=0.028) in the incidence of complications 
between the two groups of patients in our study with 30 complications (29.1%) in the 
laparotomy group and 5 in the laparoscopy group (11.9%). There was no wound related 
morbidity in the laparoscopy group.  
 
 
The complications in the laparoscopy included two cardiac related events, one 
pelvic collection, one ureteric injury and re-implantation and one urinary infection, thus 
leading to only two surgery-related complications. This was similar to the reported 
complication rates for laparoscopic surgery by Eltabbakh et al (35) - 10.5%, more than 
the reports by Gemignani et al. (52) – 5.8%, Childers et al. – 5.1% (26), but less than that 
reported by Boike et al - 25% (54) and Magrina et al. (55) 
 
 
In the laparotomy group, there were 19 surgical site wound problems some of 
them needing secondary suturing and thus prolonging hospital stay. There was one 
patient with burst abdomen needing tension repair. One late post- operative complication 
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occurred in the form of obstructed incisional hernia needing emergency re-exploration 
and repair. Post operative ileus occurred in 3 patients causing a stoppage of and re-
initiation of oral feeds.  
Two patients developed pelvic collections which were managed conservatively. 
The other complications in this group were related to urinary or respiratory infection and 
cardiac related events.  
 
  
It was also found that in both groups the hospital stay was significantly prolonged 
in both the groups in those patients in whom complications occurred. (p=0.003 in open 
surgical staging and p<0.001 in laparoscopic staging) As a direct consequence of this, the 
potential for prolonged hospital stay as a result of complications is also reduced. Also 
laparoscopic surgical staging significantly reduced complications especially surgical site 
infection.  
 
 
The conversion rate to laparotomy in our study was 4.76% i.e. in two patients, 
both due to intra-operative bleed. The rates quoted were Gemignani et al. (52) - 4.3%, 
Eltabbakh et al (35) – 5.8%, Childers et al. – 13.6% (26), Boikee et al – 13% (54), and 
Spirtos et al.-0% (51). The conversion rate is comparable to that mentioned in the above 
studies and is bound to come down with the experience of the surgeon though excessive 
adhesions, bleed obscuring vision or cardiopulmonary problems intra-operatively due to 
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increased positive pressure induced by insufflation still occasionally necessitate 
conversion.  
 
 
Among the pathological parameters analysed, the median size of the uterus 
specimen was 9 cm (range 5-16 cm) in the open surgery group and 8.5 cm (range 7-13 
cm) in the laparoscopy group (p=0.075). In all patients the specimen was delivered per 
vaginum and there was no patient who required a mini laparotomy to deliver the 
specimen. There was no evidence of vagina or parametrial margin positivity on 
pathological examination.  
 
 
The median pelvic nodal yield in our study was 13 in the laparoscopic surgery 
group (range 4-41) and 12 in the open surgery group (range 3-30) and the difference was 
not statistically significant (p=0.488). Subgroup analysis revealed that the pelvic nodal 
yield in the laparoscopic surgery group improved from a median of 10 nodes in the initial 
21 surgeries to 16 in the next 21 patients.  
 
The pelvic nodal yield mentioned in various studies is comparable viz. Eltabbakh 
et al – 10.8 (39), Ghezzi et al. - 18 (45), Volpi et al – 15.9 (46), Eisenhauer et al – 15 (49) 
and Malur et al. – 16.1 (36). The other studies also mention the improvement in the nodal 
yield with surgeon experience.   
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The most common pathological stage was Stage I in both open and laparoscopic 
surgery group 76% in open staging and 69% in the laparoscopy group.  This is in 
concordance with the natural history of the disease and the percentages mentioned in 
various studies where Stage I tumours were the commonest stage at presentation (Tay et 
al. - 92% (48), Eltabbakh et al – 80.2% (35), Ghezzi et al. -  83.8% (45), Volpi et al – 
82.9%  (46) and Eisenhauer et al – 92% (49). Many of the Western studies had a higher 
representation of stage I disease probably because of earlier identification of the 
malignancy compared to our study population because of greater awareness and the early 
reporting to health care providers in the Western setup.  
     
 The analysis of disease free and overall survival in our study was the secondary 
objective. The median follow-up for the laparoscopy group was 1.67 years (range 0.1 to 
3.26) and 3.27 years for the laparotomy group (range 0.1 to 5.78). The difference is also 
seen in many of the retrospective studies - Eltabbakh et al – 24 and 48 months (35), and 
Ghezzi et al. - 52 and 80 months (45).  
 
Previous studies have shown that 76% of the recurrences occur within the first 
three years. The median time to recurrence was 14 months for patients with local 
recurrence and 19 months for those with distant metastases (56). In our study there were 
10 recurrences, eight in the open surgery group (7.7%) and two (4.76%) in the 
laparoscopic staging group. There were no local recurrences in the laparoscopy group – 
one patient had lung metastases and the other had brain metastases. Among the patients in 
open surgery group, there were three regional recurrences that were salvaged by 
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radiation. The difference in the site and incidence of recurrences was not statistically 
significant.  
The recurrence rates reported by other authors with similar studies were 7% and 
10.5% for by Eltabbakh et al (35), 11.1% and 15.6% by Ghezzi et al. (45), and 9% and 
11% by Magrina et al. (55).  
 
 The two year DFS for the open and laparoscopic surgery groups was 98% and 
96% respectively while the 2 year OS was 98% and 94% respectively. There were ten 
deaths in our study population – eight in the open surgery group and two in the 
laparoscopic surgery group. The cause specific mortality was 2.75%. Only four deaths 
were attributable to advanced carcinoma endometrium. Four deaths were due to 
progression of carcinoma breast in patients who developed tamoxifen induced 
endometrial cancers and two deaths were not related to cancer. 
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CONCLUSION 
 
 
 Carcinoma endometrium is showing a rising incidence in our country. The 
essential management of this malignancy is surgical with extended staging being the 
recommendation for all patients. The surgical staging is traditionally accomplished by 
laparotomy but the advent of laparoscopy has made possible this minimally invasive 
option to be used for achieving the same ends. 
 
 The median age of our study population is about 8 years lower than that of the 
Western world. Also our patients tend to have a lower BMI and there is no impact of 
BMI on the ability to perform a safe laparoscopic staging. There is no statistically 
significant difference in the use of laparoscopy in patients with co-morbid conditions. 
 
 Laparoscopic surgery results in significant reduction in hospital stay and 
incidence of complications especially surgical site infections and paralytic ileus. While it 
is associated with a significantly prolonged operating time, there is no difference in the 
median blood loss compared to open surgery.  
 
 The grade and stage distribution are comparable in the laparotomy and 
laparoscopy groups and the pelvic nodal yield is equal if not better in the latter group. 
There is also a trend towards improving nodal yield with the increasing surgical 
experience of the operating surgeon.  
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 Though long term data are not available, short term results show that there is no 
significant difference in the 2-year overall survival and disease free survival between the 
two groups nor do they show any statistically significant difference in the recurrence rate 
or disease specific mortality. 
 
 Similar to colorectal cancers where laparoscopic surgery has been proved to have 
short term advantages with equivalent long term oncologic outcomes, the laparoscopic 
surgical staging in carcinoma endometrium can be performed as safely as the 
conventional open approach without compromising on the operative, pathological and 
oncologic outcomes and has the added advantage of fewer complications and decreased 
hospital stay. 
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ABSTRACT 
 
Endometrial adenocarcinoma ranks third among gynaecological malignancies after 
cervix and ovarian cancer in India. The foundation of management of endometrial carcinoma 
is surgical staging in the form of peritoneal biopsies, omentectomy and pelvic and para aortic 
lymphadenectomy. The surgical staging is traditionally accomplished by laparotomy but the 
advent of laparoscopy has made possible this minimally invasive option to be used for 
achieving the same ends. 
 A retrospective analysis of all patients who presented with adenocarcinoma of the 
endometrium and treated surgically at the Cancer Institute (WIA) from the year 2006 to 2010 
was done. A total of 145 patients with adenocarcinoma of the endometrium that underwent 
surgical staging by open or laparoscopic method were analysed. Patient factors like age, BMI 
and co-morbid illnesses were not significantly different in the two groups. Laparoscopic 
surgery resulted in significant reduction in hospital stay and incidence of complications 
especially surgical site infections and paralytic ileus. While it was associated with a 
significantly prolonged operating time, there was no difference in the median blood loss 
compared to open surgery. The grade and stage distribution were comparable in the 
laparotomy and laparoscopy groups and the pelvic nodal yield was equal if not better in the 
latter group with a trend towards improving nodal yield with the increasing surgical 
experience of the operating surgeon.  
 Though long term data was not available, short term results showed that there was no 
significant difference in the 2-year overall survival and disease free survival between the two 
groups was there any statistically significant difference in the recurrence rate or disease 
specific mortality thus proving that laparoscopic approach to surgical staging in carcinoma 
endometrium can be performed as safely as the conventional open approach without 
compromising on the operative, pathological and oncological outcomes. 
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